Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
By Ben Glickman
Shares of Nurix Therapeutics rose Tuesday after the company said it had extended its strategic collaboration with Sanofi.
The stock was up 19% to $16.42 in afternoon trading, reaching its highest intraday level since September 2022. Shares have risen about 55% since the start of the year.
The biopharmaceutical company said that it and Sanofi are looking to nominate a development candidate from the program within the first year of the extended term.
The research program is studying STAT6, a key drug target for certain types of inflammation. The program uses Nurix's platform to identify new compounds that use certain enzymes to affect drug targets.
Under the agreement between the two companies, Sanofi has an option to license drug candidates resulting from the collaboration. Nurix has the option to co-develop and co-promote future products in the U.S. for certain programs.
The deal has been in place since December 2019.
Nurix also on Tuesday said it had presented its findings of clinical responses in the brain for one of its drug candidates, NX-5948, at a conference. Chief Scientific Officer Gwenn Hansen said in a statement that the results suggested a potential role for the compound in the treatment of B-cell lymphomas and some forms of lymphocytic leukemia.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 09, 2024 13:57 ET (17:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing